204 related articles for article (PubMed ID: 35301821)
1. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821
[TBL] [Abstract][Full Text] [Related]
2. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.
Cortellini A; Palumbo P; Porzio G; Verna L; Giordano AV; Masciocchi C; Parisi A; Cannita K; Ficorella C; Bozzetti F
Thorac Cancer; 2018 Dec; 9(12):1623-1630. PubMed ID: 30259689
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study.
de Jong C; Herder GJM; Deneer VHM
Thorac Cancer; 2020 Dec; 11(12):3634-3640. PubMed ID: 33073546
[TBL] [Abstract][Full Text] [Related]
4. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
[TBL] [Abstract][Full Text] [Related]
6. Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients.
Grønberg BH; Valan CD; Halvorsen T; Sjøblom B; Jordhøy MS
J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1347-1355. PubMed ID: 31385663
[TBL] [Abstract][Full Text] [Related]
7. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer.
Sjøblom B; Grønberg BH; Benth JŠ; Baracos VE; Fløtten Ø; Hjermstad MJ; Aass N; Jordhøy M
Lung Cancer; 2015 Oct; 90(1):85-91. PubMed ID: 26198373
[TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
9. Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer.
Halvorsen TO; Valan CD; Slaaen M; Grønberg BH
J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1283-1290. PubMed ID: 32725772
[TBL] [Abstract][Full Text] [Related]
10. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
Antoun S; Bayar MA; Dyevre V; Lanoy E; Smolenschi C; Ducreux M
BMC Cancer; 2019 Aug; 19(1):847. PubMed ID: 31462288
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
12. The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy.
Huiskamp LFJ; Chargi N; Devriese LA; de Jong PA; de Bree R
Eur Arch Otorhinolaryngol; 2020 Oct; 277(10):2847-2858. PubMed ID: 32335709
[TBL] [Abstract][Full Text] [Related]
13. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer.
Chargi N; Bashiri F; Wendrich AW; Smid EJ; de Jong PA; Huitema ADR; Devriese LA; de Bree R
Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3685-3694. PubMed ID: 35038029
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
15. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.
Atlan P; Bayar MA; Lanoy E; Besse B; Planchard D; Ramon J; Raynard B; Antoun S
Support Care Cancer; 2017 Nov; 25(11):3365-3373. PubMed ID: 28593463
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.
Naito T; Okayama T; Aoyama T; Ohashi T; Masuda Y; Kimura M; Shiozaki H; Murakami H; Kenmotsu H; Taira T; Ono A; Wakuda K; Imai H; Oyakawa T; Ishii T; Omori S; Nakashima K; Endo M; Omae K; Mori K; Yamamoto N; Tanuma A; Takahashi T
BMC Cancer; 2017 Aug; 17(1):571. PubMed ID: 28841858
[TBL] [Abstract][Full Text] [Related]
17. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
18. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer.
Sjøblom B; Benth JŠ; Grønberg BH; Baracos VE; Sawyer MB; Fløtten Ø; Hjermstad MJ; Aass N; Jordhøy M
Clin Lung Cancer; 2017 Mar; 18(2):e129-e136. PubMed ID: 27825639
[TBL] [Abstract][Full Text] [Related]
19. Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage I non-small cell lung cancer.
Matsuo Y; Mitsuyoshi T; Shintani T; Iizuka Y; Mizowaki T
J Geriatr Oncol; 2018 Nov; 9(6):589-593. PubMed ID: 29779799
[TBL] [Abstract][Full Text] [Related]
20. Impact of pre-treatment C-reactive protein level and skeletal muscle mass on outcomes after stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis of the Japan Clinical Oncology Group study JCOG0403.
Matsuo Y; Nagata Y; Wakabayashi M; Ishikura S; Onishi H; Kokubo M; Karasawa K; Shioyama Y; Onimaru R; Hiraoka M
J Radiat Res; 2021 Sep; 62(5):901-909. PubMed ID: 34350956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]